Target	Probe	Control	Targeted domain	Mode of action	Recommended concentration	Target origin
EDNRA	ABT-546	A-545	—	Antagonist	≤ 100 nM	human
DRD4	ABT-724	A-769	—	Agonist	1 - 10000 nM	human
EDNRB	A-192621	A-1806262	—	Antagonist	≤ 300 nM, probe < 1 µM	human
AVPR1A, AVPR2	BAY 1753011	BAY-2297	—	Antagonist	100 nM	human
CCR1	BAY-3153	BAY-173	—	Antagonist	≤ 100 nM	human
F2R	BAY-386	BAY-448	—	Antagonist	≤ 100 nM	human
ADRA2B	BAY-6096	BAY-726	GLN-168, ASP-92, PHE-388 direct interaction with ligand	Antagonist	100 nM	human
PTGFR	BAY-6672	BAY-403	—	Antagonist	≤ 0.5 µM	human
GNRHR	BAY-784	BAY-786	—	Antagonist	≤ 1 µM	human
LHCGR	BAY-899	BAY-897	Remnants of the rhodopsin binding site	Allosteric antagonist	1 µM	human
BDKRB1	BI-113823	BI-5832	—	Antagonist	100 nM	human
FFAR1	BI-2081	BI-0340	—	Agonist	200 nM	human
HCRTR1	BI-5121	BI-6199	Orthosteric pocket	Antagonist	100 nM	human
CCR1	BI 639667	BI-9307	—	Antagonist	100 nM	human
NPY1R	BIBO3304	BIBO3457	—	Antagonist	100 nM	human
PTAFR	WEB2086	WEB2387	—	Antagonist	300 nM	human
LTB4R2	T-10430	T-10404	—	Agonist	≤ 100 nM	human
HRH4	JNJ-39758979	JNJ-39668551	—	Orthosteric antagonist	≤ 10 µM	human
PTGDR2	CRTH2 antagonist	CRTH2 negative control	—	Antagonist	100 nM	human
CNR1	MRL-650	MRL-CB1-NC	—	Inverse agonist	≤ 1 µM	human
CHRM1	MSD-M1PAM	MSD-M1PAM-NC	—	Positive allosteric modulator	< 1 µM	human
P2RY14	PPTN	PPTN-NC	—	Antagonist	100 nM	human
PTGER2	PF-04418948	PF-04475866	—	Antagonist	< 300 nM	human
KISS1R	KISS1-305	KISS1-543	Kisspeptin binding site	Agonist	1 - 1000 nM	human
ADRA1D	(R)-9s	(S)-9s	—	Antagonist	≤ 1 µM	human
GPR52	TP-024	TP-024n	—	Agonist	1 µM	human
FFAR1	TP-051	TP-051n	Pocket between TM1 and TM3	Agonist	≤ 1 µM	human
DRD4	UCSF924	UCSF924NC	Dopamine binding site	Agonist	1 µM	human
MRGPRX2	(R)-ZINC-3573	(S)-ZINC-3573	TM5 (Asp184)	Agonist	≤ 1 µM	human
GPR68	Ogerin	ZINC32547799	—	Positive allosteric modulator	≤ 1 µM	human